Fig. 6: The association of enasidenib drug approval date and residual IDH2 mutations on clinical outcomes.
From: Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Cumulative incidence of relapse on the left and non-relapse related mortality (NRM) on the right for IDH2-mutated AML patients based on the date of transplant occurring before or after the approval date of enasidenib (August 2017) and the presence (IDH2 NGS MRDpos) or absence (IDH2 NGS MRDneg) of residual IDH2 variants.
